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Abstract
This study aimed to assess analytical parameters of a prototype LAMP kit that was designed
for detection of Trypanosoma cruzi DNA in human blood. The prototype is based on the
amplification of the highly repetitive satellite sequence of T.cruzi in microtubes containing
dried reagents on the inside of the caps. The reaction is carried out at 65˚C during 40 min-
utes. Calcein allows direct detection of amplified products with the naked eye. Inclusivity
and selectivity were tested in purified DNA from Trypanosoma cruzi stocks belonging to the
six discrete typing units (DTUs), in DNA from other protozoan parasites and in human DNA.
Analytical sensitivity was estimated in serial dilutions of DNA samples from Sylvio X10 (Tc I)
and CL Brener (Tc VI) stocks, as well as from EDTA-treated or heparinized blood samples
spiked with known amounts of cultured epimastigotes (CL Brener). LAMP sensitivity was
compared after DNA extraction using commercial fiberglass columns or after “Boil & Spin”
rapid preparation. Moreover, the same DNA and EDTA-blood spiked samples were sub-
jected to standardized qPCR based on the satellite DNA sequence for comparative pur-
poses. A panel of peripheral blood specimens belonging to Chagas disease patients,
including acute, congenital, chronic and reactivated cases (N = 23), as well as seronegative
controls (N = 10) were evaluated by LAMP in comparison to qPCR. LAMP was able to
amplify DNAs from T. cruzi stocks representative of the six DTUs, whereas it did not amplify
DNAs from Leishmania sp, T. brucei sp, T. rangeli KPN+ and KPN-, P. falciparum and non-
infected human DNA. Analytical sensitivity was 1x10-2 fg/μL of both CL Brener and Sylvio
X10 DNAs, whereas qPCR detected up to 1x 10−1 fg/μL of CL Brener DNA and 1 fg/μl of Syl-
vio X10 DNA. LAMP detected 1x10-2 parasite equivalents/mL in spiked EDTA blood and
1x10-1 par.eq/mL in spiked heparinized blood using fiberglass columns for DNA extraction,
whereas qPCR detected 1x10-2 par.eq./mL in EDTA blood. Boil & Spin extraction allowed
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LAMP was able to detect T.cruzi infection in peripheral blood samples collected from well-
characterised seropositive patients, including acute, congenital, chronic and reactivated
Chagas disease. To our knowledge, this is the first report of a prototype LAMP kit with
appropriate analytical sensitivity for diagnosis of Chagas disease patients, and potentially
useful for monitoring treatment response.
Author summary
Trypanosoma cruzi, a parasite transmitted to humans from hematophagous insects, causes
Chagas Disease, a Neglected Tropical Disease with public health impact, affecting 7 mil-
lion people in Latin America. Although mainly related to low income populations inhabit-
ing rural environments, migrations have conveyed Chagas Disease to urban areas of
endemic and non-endemic countries. It often presents non-specific symptoms, and direct,
low cost microscopy-based diagnosis only detects acute infections, missing a high propor-
tion of cases. Serology is the “gold standard” diagnostic technique for chronic stages and
needs the concordance of at least two different assays to confirm infection. In this context,
we aimed to evaluate the analytical sensitivity and specificity of a prototype kit based on a
novel and rapid molecular biology reaction, named Loop mediated isothermal amplifica-
tion (LAMP), using standardized Real Time PCR as a comparator. To our knowledge, this
is the first LAMP prototype kit with an analytical performance appropriate for human
diagnosis of Chagas disease and potentially useful for monitoring treatment response. Its
simple handling using basic laboratory devices will enable point-of-care diagnosis and
screening for congenital infection at birth as well as early detection of acute infections due
to oral contamination.
Introduction
Chagas disease, caused by the parasite Trypanosoma cruzi, remains a major concern in 21
endemic countries of Latin America, where infection is acquired mainly through the triato-
mine insect vector. Due to migration movements, it has spread over other continents, with 6
to 7 million people estimated to be infected. T. cruzi infection can also be transmitted by blood
transfusion, the trans-placental route causing Congenital Chagas disease, oral contamination,
organ transplantation and laboratory accident [1].
Two disease stages can be distinguished and the strategies for diagnosis are stage-depen-
dent. Firstly, a short acute stage occurs with patent parasitemia that can be detected using con-
ventional parasitological techniques, such as parasite microscopic observation in blood smears
or microhematocrite, xenodiagnosis and hemoculture. However, these methods usually lack
sensitivity and are operator dependent, and the last two mentioned techniques are cumber-
some and their results can be acquired only several weeks after sample collection [2]. In a
majority of acute cases, symptoms are not evident and thus the infection mostly goes undiag-
nosed; it enters in an indeterminate chronic period that may span life-time in around 70% of
cases. In the remaining 30%, chronic stage leads to cardiomyopathy and/or digestive megasyn-
dromes, causing death if untreated. As in the chronic phase, parasitemia is intermittent and
low, diagnosis is largely made by serological tests. Due to the antigenic variability of the
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parasite, WHO’s guidelines recommend to perform at least two serological assays based on dis-
tinct antigen sets, which must agree for a conclusive diagnosis [1].
The different transmission modes, the disease phases and the high genetic variability of the
parasite increase the difficulties of making diagnostic kits with most appropriate markers for
the diverse Chagas disease epidemiological settings. Nucleic acid amplification strategies have
opened new options to detect T. cruzi infection and evaluate anti-parasitic chemotherapy.
Diagnostic assays for Chagas disease need improvement. The development of diagnostic
test for the following areas have been identified as a priority: acute phase, including oral and
congenital transmission and monitoring of anti-parasitic treatment response [2, 3,]. The use of
Loop-mediated isothermal amplification (LAMP) of DNA has been proposed as an outstand-
ing approach to bridge some of these gaps [3]. LAMP is a platform developed by Eiken Chemi-
cal Company of Japan (http://www.eiken.co.jp/en). This technology detects known genes from
different pathogens [4] [5] [6]. It has the following characteristics: (1) only one enzyme is used
and the amplification reaction proceeds under isothermal conditions [7] [8]); (2) extremely
high specificity because of the use of four primers recognizing six distinct regions on the target;
(3) high amplification efficiency, with DNA being amplified 109−1010 times within 15–60 min-
utes of incubation; and (4) it produces tremendous amounts of amplification product, making
simple visual detection possible [8] [9]. Due to the above mentioned characteristics, LAMP
can be performed in basic laboratories without the need for specialized infrastructure and it is
appropriate for field applications and point-of-care diagnosis. Several of these kits are quite
mature, such as the Tuberculosis and Malaria assays which are already commercialized Loop-
amp Assays. LAMP Assays—HUMAN Diagnostics Worldwide. Available: https://www.
human.de/products/molecular-dx/isothermal-amplification/lamp-assays/)
A LAMP method for detection of T. cruzi DNA was previously designed based on the 18S
ribosomal RNA (rRNA) gene and evaluated in DNA samples extracted from internal organs of
triatomine vectors [10]. However, its low analytical sensitivity (100 fg per reaction tube) has
not allowed its application to diagnosis of Chagas disease in humans.
LAMP tests based on amplification of multicopy repetitive sequences, such as the mobile
element RIME of T. brucei [11] and the satellite DNA sequence of T. vivax [12] have been
used to improve sensitivity. Accordingly, a novel LAMP assay based on the highly repetitive
satellite DNA sequence of T.cruzi was developed to create a prototype kit for detection of this
parasite in human blood. The present study aimed to assess the analytical performance of
this kit prototype on DNA extracted from EDTA-treated as well as from heparinized human




Informed written consent was obtained from all healthy donors and Chagas disease patients
included in the study before blood collection, after permission of the IRB of the participating
institutions, in agreement with argentine legislation in force (Blood Donation Law N˚ 22990,
Res. N˚1409/15)
Participants
Peripheral blood samples from a total of 23 well-characterised Chagas disease patients and 10
seronegative controls were tested by LAMP and qPCR. Four clinical groups with T.cruzi infec-
tion were evaluated, namely Group CI: Samples from five newborns/neonates born to Chagas
disease women; Group AI-TXRI: samples from three transplanted seronegative receptors of
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organs from a seropositive donor that acquired acute T.cruzi infection; Group CCD: samples
from ten chronic Chagas disease patients; Group RCD: samples from five chronic Chagas dis-
ease patients undergoing clinical reactivation due to immunosuppression after organ trans-
plantation. All cases and controls were admitted at Health Centers of Argentina.
Parasitic strains
T. cruzi stocks belonging to the six discrete typing units (DTUs) [13] were used in the present
study. Sylvio X10 (Tc I) and CL-Brener (Tc VI) are available at INGEBI since year 2009 and
their identity is periodically assessed by multiplex Real Time PCR [14]. JG1 (Tc II), M6241 (Tc
III) and M4167 (Tc IV) were kindly provided by Dr Constança Britto and Otacilio Moreira
(Instituto Oswaldo Cruz, Rio de Janeiro, Brasil) and PAH179 (Tc V) by Dr Patricio Diosque
(Instituto de Parasitologı́a Experimental—IPE, University of Salta, Salta, Argentina). Strains
were cultured using LIT medium and DNAs were purified using phenol-chloroform extrac-
tion followed by ethanol precipitation.
DNAs from Leishmania sp. and T.rangeli were kindly provided by Dr. Concepción Puerta
from Pontificia Universidad javeriana—PUJ University, Bogotá, Colombia and DNA from T.
brucei sp. and P. falciparum by Dr Yasuyoshi Mori from Eiken Chemical Company, Japan.
All DNAs were measured with microvolume UV-Vis spectrophotometer (Nanodrop 1000,
Thermo Scientific, with nd_1000-v.3.8.1 software).
DNA extraction for LAMP testing
DNA was extracted from EDTA blood and heparinized blood samples, using two different
preparation procedures:
a) Blood based-DNA for LAMP was obtained from 200 μL of EDTA-blood using the High
Pure PCR Template Preparation Kit with packed fiberglass filter tubes, cell lysis buffer and
proteinase K (RAS extraction kit, Roche Applied Sciences, Mannheim, Germany) with one
additional step prior to the addition of 100 μL of elution buffer, which consists of spinning the
columns after the second wash to eliminate any traces of isopropanol and b) a Boil & Spin
rapid procedure modified according to the type of blood sample: b1) Boil & Spin of EDTA-
blood samples: 200 μL of blood were mixed with 200 μL of 0.5% SDS in double distilled water
in a 1.5 mL microtube with screwcap and o-ring by vortex (10 seconds), then heated in a ther-
moblock at 95˚C for 5 min. The tube content was spun down for 5 minutes at the maximum
speed (13,300 rpm) on a bench top centrifuge. The supernatant was pipetted into a new labeled
1.5 mL flat cap microtube, ready to use immediately or stored at −20˚C for up to 48 h, prior to
use in the LAMP reaction, with only one freeze-thaw cycle before testing. b2) Boil & Spin of
heparinized blood samples: 300 μL of blood and 15 μL of 10% SDS in double distilled water
were thoroughly mixed in a 1.5 mL microtube with screwcap and o-ring by vortex (30 sec-
onds). 100 μL of the solution were withdrawn, transferred to a new tube containing 400 μL of
sterile water, then heated in a thermoblock at 90˚C for 10 minutes. The tube content was spun
down for 3 minutes at maximum speed (13,300 rpm). The supernatant was pipetted into a
new labeled 1.5 mL flat cap microtube and the previous step was repeated once. The superna-
tant was used immediately for the LAMP reaction.
DNA extraction for qPCR
Blood based-DNA for qPCR was obtained from 200 μL of EDTA-blood using the the RAS
extraction kit as detailed for LAMP assays.
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Amplification procedure for LoopampTrypanosoma cruzi prototype kit
This product is based on the nucleic acid amplification method, LAMP, developed by Eiken
Chemical Co., Ltd. Japan, using as molecular target the repetitive satellite DNA sequence of T.
cruzi. The primer sequences were designed after alignment analysis of selected database
sequences to have a relatively well-conserved sequence recognized in all six described DTUs.
The nucleotide sequence of the primers used in the study are not provided, since the assay is
being developed into a commercial product. T. cruzi Loopamp kits can be obtained from
Eiken (http://www.eiken.co.jp/en/inquiry.html.).
The reaction tube contains strand displacement Bst (Bacillus stearothermophilus) DNA
polymerase, deoxynucleotide triphosphates (dATP, dCTP, dGTP and dTTP), calcein and T.
cruzi-specific primers.
These reagents are in dried form on the inside of the cap of the reaction tube and are stable
for one year at 30˚C. A negative control (NC, distilled water) is provided in the kit. The posi-
tive control was 1fg/μL of DNA from CL-Brener stock (Tc VI).
The LAMP reaction was performed as follows: 30 μL of sample DNA extract was dispensed
into each LAMP tube, and the cap was closed. Each tube was flicked down to collect the solu-
tion at the bottom and placed upside down during two minutes to reconstitute the dried
reagent. It was inverted five times to mix the content followed by a spin down.
Incubation of the reaction was carried out at 65˚C for 40 minutes for isothermal amplifica-
tion, followed by a step at 80˚C for five minutes for enzyme inactivation using different
devices: 1) Rotor Gene 6000 thermocycler (Corbett Life Science, Cambridgeshire, UK); Per-
kin-Elmer 9600 (Thermofisher, USA) and Genie III Fluorimeter Instrument (Optigene, Hor-
sham, West Sussex, UK).The results of amplification were visualized using different strategies:
i) Real-time fluorescence data was obtained on the Rotor Gene 6000 FAM channel (excitation
at 470 nm and detection at 510 nm, auto-optimisated gain level -2, 33 after 40 cycles of 60 sec-
onds each at 65˚C to achieve an isothermal reaction followed by a hold on 80˚C during 5 min-
utes) ii) Genie III Instrument (excitation at 470 nm, detection at 510 nm, low gain level 4,
specific for calcein; the run profile settings for amplification were 65˚C, 40 min. To end reac-
tion, the anneal settings starts at 98˚C with a ramp rate of 0,06˚C/second to reach 80˚C during
5 minutes in order to inactivate the enzyme iii) visualization of fluorescence by the naked eye
iv) in some cases, 1.2% agarose gel electrophoresis with TAE (Tris-acetate with EDTA), ethid-
ium bromide and GelPilot loading dye 5x, final dilution 1x, run at 80 V (Qiagen, Hilden, Ger-
many) was carried out to corroborate the typical ladder profile of multiple bands of LAMP
products [15].
Amplification using Real Time quantitative PCR (qPCR)
The LAMP method was compared to a standardized qPCR assay that consisted of a duplex
qPCR with TaqMan probes targeted to T. cruzi satellite DNA and Internal Amplification con-
trol (IAC), as described by Duffy and coauthors [16] on the basis of the T.cruzi primer and
probe sequences published by Piron and coauthors [17], and validated following international
guidelines [16,18]. The qPCR reactions were carried out in duplicates with 5 μL of eluted DNA
in a final volume of 20 μL containing 2X FastStart Universal Probe Master Mix (Roche Diag-
nostics GmbHCorp., Mannheim, Germany), 10 μM primers cruzi 1 and cruzi 2 and probe
cruzi 3 [19]; 5 μM primer IAC FW, primer IAC Rv and probe IAC-Tq [14]. Cycling conditions
were a first step of 10 minutes at 95˚C followed by 40 cycles at 95˚C for 15 seconds and 58˚C
for 1 minute. The amplifications were carried out in an ABI7500 (Applied Biosystems, Foster
City, CA, USA) or a Rotor-Gene 6000 (Corbett Life Science, Cambridgeshire, United
LAMP kit for detection of Trypanosoma cruzi DNA
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Kingdom) thermocycler equipments. All reactions included a strong positive control (SPC):
10 fg/μL of CL Brener DNA and a weak positive control (WPC): 1 fg/μL of CL-Brener DNA.
Analytical validation of LAMP Assay
Selectivity. Inclusivity was tested in serial dilutions of purified DNAs from T. cruzi stocks
belonging to the six DTUs, namely Sylvio X10 (Tc I), JG1 (Tc II), M6241 (Tc III), M4167 (Tc
IV), PAH179 (Tc V) and CL-Brener (Tc VI).
Exclusivity was tested in purified DNAs from T. rangeli KPN+ and KPN- stocks, T.b. brucei,
T.b. gambiense, T.b. rhodesiense, Leishmania amazonensis, L. donovani, L.infantum, L. infan-
tum chagasi, L. major and L. mexicana, and Plasmodium falciparum.
Human DNA samples from blood collected from 5 individuals who were seronegative for
T. cruzi were included as specificity controls. DNA was obtained using commercial RAS col-
umns, as indicated above. Human DNA was tested without prior quantification in spectropho-
tometer, because it constitutes part of the matrix of blood samples. LAMP reactions were done
in triplicate.
Analytical sensitivity in purified DNA. To evaluate the analytical sensitivity of LAMP,
three serial ten-fold dilutions spanning 1 x 103 to 1 x 10−3 fg /μL were prepared from DNA ali-
quots of Sylvio X10 (Tc I) and CL Brener stocks (Tc VI) from an already-existing collection
from our laboratory. These strains were selected because they present the highest difference in
copy number of Satellite DNA repeats [19]. LAMP reactions were done in triplicates from
each DNA aliquot. The four most diluted samples were also tested by qPCR for comparative
purposes; three different DNA aliquots from the same DNA stock were assayed in duplicates
for each concentration.
Analytical sensitivity in spiked human blood samples. Analytical sensitivity using
spiked blood samples was carried out in EDTA-blood and heparinized blood samples
extracted using RAS extraction kit in order to explore the effects of the matrix from human
blood samples. Whole EDTA or heparinized blood collected from non-infected donors was
spiked with ten-fold serial dilutions of CL Brener cultured parasites spanning concentrations
of 1 x 103 to 1 x 10−3 parasite equivalents/mL (par.eq./mL). The term parasite equivalent
means the equivalent genomic content of one parasite cell, as the blood samples are spiked
with parasite epimastigotes manually counted using a Neubauer chamber. This stock was the
one selected for this measurement because it has been previously used to evaluate analytical
sensitivity of the standardized and validated qPCR procedure, used as a reference in this work
[16].
Evaluation of LAMP in clinical samples. A panel of peripheral blood specimens belong-
ing to well-characterized Chagas disease patients, including acute, congenital, chronic and
reactivated cases (N = 23) and seronegative controls (N = 10) were evaluated by LAMP in com-
parison to qPCR.
All samples were obtained in EDTA-tubes (BD vacutainer tubes, Becton Dickinson, USA)
and processed using the RAS kit for DNA purification. A volume of 30 μL of DNA eluate was




Inclusivity. The LAMP assay was able to detect DNA from T. cruzi stocks representative
of DTUs I to VI. The T. cruzi stocks that showed detectable LAMP results at the lowest DNA
concentrations were M6241 (Tc III, 7.5 x 10-2 fg/test) and M4167 (Tc IV, 5.0 x 10-2 fg/test) in
LAMP kit for detection of Trypanosoma cruzi DNA
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one of both tested duplicates and the stock with lowest sensitivity was JG1 (Tc II, 2.5 fg/test) in
both replicates (Fig 1 and Table 1).
Exclusivity. No LAMP products were obtained when up to 30 ng/test of DNA samples
from P. falciparum, different species of Leishmania (L.major; L. amazonensis, L.chagasi,L.dono-
vani, L. infantum, L.guyanensis and L.mexicana), T. brucei subspecies (T.brucei brucei, T.b.gam-
biense, T.b. rhodesiense) and T. rangeli (KPN + and KPN—stocks) were tested (examples in Fig
2A).
Non-infected human DNA gave negative LAMP results (Fig 2B). In order to confirm that
the negative LAMP results were not due to reaction inhibition by the high DNA concentra-
tions tested, mixtures of T. cruzi DNAs with Leishmania major or T. rangeli KPN+ were
assayed (Fig 2B). LAMP results were positive, showing that there was no inhibitory effect by
the DNA concentrations of Leishmania major or T.rangeli KPN+ (Fig 2B).
The standardized qPCR assay, used as comparator, was carried out on DNA samples from
Leishmania sp, T. rangeli KPN+ and non-infected human DNA dilutions, and negative find-
ings were observed, in agreement with LAMP results (S1 Fig).
Analytical sensitivity of LAMP assay
Analytical sensitivity was estimated on ten-fold serial dilutions done in triplicate from three
independent DNA samples of Sylvio X10 (Tc 1) and CL Brener (Tc VI) stocks (Fig 3).
The prototype LAMP kit detected T.cruzi DNA at concentrations 1 x 10−2 fg/μL (0.3 fg
per test) in both CL Brener and Sylvio X10 stocks. DNA samples spanning 1 fg/μL to 1 x 10−3
fg/μL were also assayed by qPCR for comparative purposes (S2 and S3 Figs). The qPCR
detected up to 1 x 10−1 fg/μL of CL Brener DNA (S2 Fig) and 1 fg/μL of Sylvio X10 DNA,
whereas 1 x 10-1fg/μL of the latter was detectable in only one aliquot (S3 Fig, aliquot A1).
Analytical sensitivity and specificity of LAMP assay in spiked blood
samples
The analytical sensitivity of LAMP was tested in EDTA and heparinized-blood samples spiked
with known parasite loads (par.eq./mL).
EDTA blood samples spiked with CL Brener DNA showed positive LAMP results when
using the RAS extraction kit (6 x 10−4 par.eq. per test; Fig 4A) and the Boil & Spin preparation
method (3 x 10−4 par.eq. per test; Fig 4B).
The qPCR was carried out in spiked EDTA blood samples following the standardized pro-
cedure, which gave a sensitivity of 1 x 10−2 par.eq./mL (S1 Table)
Heparinized-blood. Spiked heparinized blood samples processed by RAS extraction kit
detected up to 1 x 10−1 CL Brener par.eq/mL (6 x 10−3 par.eq per test) (Fig 5A).
When processed by Boil & Spin, reactions starting from 30 μLs of DNA preparation pre-
sented a reddish appearance that precluded visualization by the naked eye, whereas agarose
gels showed the occurrence of amplification (Fig 5B).
Only after performing serial ten-fold dilutions of the Boil & Spin DNA preparation, direct
visualization was possible when at least 1:100 dilutions were used, between the range 102 to 1
par.eq./mL (S4 Fig).
Evaluation of Clinical Specimens using LAMP and qPCR
A panel of peripheral blood specimens belonging to Chagas disease patients (N = 23), as well
as seronegative controls (N = 10) were evaluated by LAMP in comparison to qPCR. LAMP
allowed detection of T.cruzi DNA in all congenital Chagas disease (CI), seronegative receptors
of organs from seropositive donors with acute infection (AI-TXRID) and reactivated Chagas
LAMP kit for detection of Trypanosoma cruzi DNA
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Fig 1. Inclusivity of LAMP assay tested in purified DNA samples from T. cruzi strains representative of
the different discrete type units. Left panels: Visualization by the naked eye of T. cruzi DNA stocks
representative of different DTUs. Tc I (A: 1.0 x10-2 fg/test; B: 1.0 x10-3 fg/test); Tc II (C: 2.5 fg/test; D: 2.5x10-1
fg/test); Tc III (E: 7.5 x 10−2 fg/test; F: 7.5 x 10−3 fg/test); Tc IV (G: 5.0 x 10−1 fg/test, H: 5.0 x 10−2 fg/test); Tc V
(I: 1.5 x 10−1 fg/test; J: 1.5 x 10−2 fg/test); Tc VI (K: 1.0 x 10−1 fg/test; L. 1.0 x 10−2 fg/test) Right panels:
Amplification plots obtained in the LAMP reaction after analyzing the samples in a Rotor Gene 3000
thermocycler. Y axis represents fluorescence and x axis represents Cts (Threshold cycles). Only the highest
dilution giving amplification and the next dilution giving non detectable results are shown.
https://doi.org/10.1371/journal.pntd.0005779.g001
Table 1. INCLUSIVITY in Trypanosoma cruzi strains representative of different DTUs (fg/test).
Tc I (Sylvio X10) 1.0 x 10−1 1.0 x 10−2 1.0 x 10−3 1.0 x 10−4
Naked eye detection +/- + /- -/- -/-
Real Time mean Ct× 23.25 27.8 NDt/NDt NDt/NDt
Tc II (JG1) 2.5 2.5 x 10−1 2.5 x 10−2 2.5 x 10−3
Naked eye detection +/+ -/- -/- -/-
Real Time mean Ct 13.47 NDt/NDt NDt/NDt NDt/NDt
Tc III (M6241) 7.5 x 10−1 7.5 x 10−2 7.5 x 10−3 7.5 x 10−4
Naked eye detection +/+ +/- -/- -/-
Real Time mean Ct 8.68 11.81/NDt NDt/NDt NDt/NDt
Tc IV (M4167) 5.0 5.0 x 10−1 5.0 x 10−2 5.0 x 10−3
Naked eye detection +/+ +/+ +/- -/-
Real Time mean Ct 8.66 11.88 12.74/NDt NDt/NDt
Tc V (PAH179) 1.5 1.5 x 10−1 1.5 x 10−2 1.5 x 10−3
Naked eye detection +/+ +/+ -/- -/-
Real Time mean Ct 10.20 12.98 NDt/NDt NDt/NDt
Tc VI (CL-Brener) 1.0 1.0 x 10−1 1.0 x 10−2 1.0 x 10−3
Naked eye detection +/- +/- -/- -/-
Real Time mean Ct 12.68 25.24 NDt/NDt NDt/NDt
. NDt: Non detectable. X When only one replicate was LAMP positive, the Ct of that sample was reported.
https://doi.org/10.1371/journal.pntd.0005779.t001
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disease (RCD) patients, in agreement with qPCR positivity (Table 2). However, in a panel of
samples from ten chronic Chagas disease patients (CCD), LAMP detected T.cruzi DNA in
four, whereas qPCR was positive in three, suggesting higher sensitivity of LAMP with respect
to qPCR. LAMP gave negative results in samples from ten seronegative patients in agreement
with qPCR results (Table 2, NI).
Examples of the tested cases are illustrated in Fig 6 (LAMP results) and S5 Fig (qPCR
results).
Discussion
Clinical molecular diagnosis of Chagas disease is important for: (i) early diagnosis of congeni-
tal transmission in newborns when presence of maternal anti-T. cruzi antibodies may deliver
false positive results [20], (ii) early detection of infection in transplant receptors of organs
from a Chagas positive donor [21], (iii) monitoring of parasite reactivation in chronically
infected patients immune-suppressed due to organ transplantation [22] or AIDS [23], and (iv)
the evaluation of new treatments in clinical trials, because detection of serological negative
Fig 2. Exclusivity of LAMP assay tested in purified DNA samples from T. rangeli, Leishmania major
stocks and non-infected human DNA. Top Panel. (A): Leishmania major DNA was tested at 1.0 x 101fg/ μL;
(B) 1.0 x .102 fg/ μL; (C) 1.0 x 103 fg/ μL; (D) 1.0 x. 104 fg/ μL. T. rangeli DNA was tested (E) at 1.0 x 104 fg/ μL
and (F) 1.0 x .103 fg/μL. Bottom Panel. (A): Mixture containing equal volumes of T. cruzi and Leishmania
major DNA at 1.0 x 104 fg/μL. (B): Mixture containing equal volumes of T. cruzi and T. rangeli DNA at 1.0 x 104
fg/μL. (C): T. cruzi DNA tested at 10 fg/μL. (D) and (E): T. rangeli DNA tested at 10 and 100 fg/μL,
respectively. NIHB: Non-infected human DNA. PC: Positive Control. NC: Negative Control.
https://doi.org/10.1371/journal.pntd.0005779.g002
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conversion in seropositive patients showing a favorable treatment outcome is impractical from
a study time perspective [24] [25].
This work aimed to assess the performance of a LAMP kit prototype targeted to satellite T.
cruzi DNA, a highly repetitive and conserved sequence in all characterized T.cruzi strains.
The prototype kit has the advantage of using reagents in dried form on the inside of the cap
of the reaction tubes. Moreover, the use of calcein allows direct visualization of amplification
by the naked eye. Calcein is included in the reaction tubes in a quenched state, bound to man-
ganese ions. Once the LAMP reaction starts, pyrophosphate ions that are generated bind to the
manganese ions, releasing calcein and generating fluorescent light. Furthermore, the presence
of magnesium ions in the buffer system enhance calcein fluorescence [9].
Analytical sensitivity and specificity of the kit prototype was carried out using purified
DNA from different parasite stocks representative of the six T. cruzi DTUs, as well as from
human blood samples anti-coagulated with EDTA or with heparin and spiked with known
quantities of T. cruzi cells. Furthermore, the prototype was evaluated in a blind panel of
peripheral blood samples from well characterized Chagas disease patients at different stages
and with different clinical manifestations, as well as seronegative donors as non-infected con-
trols (Table 2 and S5 Fig).
The LAMP kit was able to amplify DNA from all tested T.cruzi stocks by the naked eye and
by Real Time detection of fluorescence in a Rotor Gene Corbett Thermocycler (Table 1).
Fig 3. Analytical sensitivity of LAMP assay. Top panel: Fluorescence observed with the naked eye from serial
dilutions obtained from 3 different aliquots of DNA from CL Brener stock (DTU VI). Bottom panel: Fluorescence
observed with the naked eye from serial dilutions obtained from 3 different aliquots of DNA from Sylvio X10 stock.The
aliquots were expressed in fg/μL. A: 0; B: 1.0 x 10−3; C: 1.0 x 10−2; D: 1.0 x 10−1, E: 1. NC: Non template control.
https://doi.org/10.1371/journal.pntd.0005779.g003
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Fig 4. Analytical sensitivity of LAMP assay in spiked EDTA blood samples. EDTA blood samples spiked
with different quantities of purified T. cruzi DNA were processed using RAS columns or the Boil & Spin
method. (A) EDTA blood processed using RAS columns. (B): EDTA blood processed by Boil & Spin method.
Upper panels: LAMP reaction products analyzed by electrophoresis in 1.2% agarose gels and stained with
ethidium bromide. Bottom panels: pictures of LAMP reaction products visualized by the naked eye.
https://doi.org/10.1371/journal.pntd.0005779.g004
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Fig 5. Analytical sensitivity of LAMP assay done in spiked heparinized blood samples extracted using
commercial columns or Boil & Spin procedure. A. Heparinized blood processed by RAS columns. B.
Heparinized blood processed by Boil & Spin method. For each DNA extraction method, samples were
visualized with the naked eye and reaction products were observed after 1.2% agarose gel electrophoresis
and ethidium bromide staining.
https://doi.org/10.1371/journal.pntd.0005779.g005
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Analytical sensitivity was calculated for Tc I and Tc VI stocks, among other parasite strains,
and was higher than the analytical sensitivity observed with the same stocks using standardized
qPCR based on the same target [16]. The kit does not intend to discriminate between DTUs.
Variations in Cts among T.cruzi stocks can be explained due to the heterogeneity in copy num-
bers of satellite repeats [19], however sensitivity was high for all tested strains. Indeed, satellite
DNA has been successful as a molecular target for LAMP assays to detect infections by T.
vivax [12] and to implement a direct dried blood based diagnostic tool for Human African try-
panosomiasis [11] [26].
Table 2. Clinical specimens results from LAMP test and qPCR as a comparator.
Patient ID Clinical Group q PCR RESULT Ct (average) Parasitic load (par.eq./mL) LAMP RESULT
1 CI1 Positive 25.05 53.05 Positive
2 CI2 Positive 24.46 75.31 Positive
3 CI3 Positive 25.44 37.47 Positive
4 CI4 Positive 27.44 12.90 Positive
5 CI5 Positive 28.63 5.26 Positive
6 AI-TXRID 1 Positive 18.74 2939.50 Positive
7 AI-TXRID 2 Positive 27.20 11.50 Positive
8 AI-TXRID 3 Positive 18.25 4060.50 Positive
9 CCD 1 Positive 27.45 10.50 Positive
10 CCD2 Positive 29.01 3.50 Positive
11 CCD3 Positive 26.20 22.00 Positive
12 CCD4 Negative ND ND Positive
13 CCD5 Negative ND ND Negative
14 CCD6 Negative ND ND Negative
15 CCD7 Negative ND ND Negative
16 CCD8 Negative ND ND Negative
17 CCD9 Negative ND ND Negative
18 CCD10 Negative ND ND Negative
19 RCD 1 Positive 27.85 7.50 Positive
20 RCD 2 Positive 22.83 201.50 Positive
21 RCD 3 Positive 24.45 70.00 Positive
22 RCD 4 Positive 29.34 2.50 Positive
23 RCD 5 Positive 28.04 7.00 Positive
24 NI 1 Negative ND ND Negative
25 NI 2 Negative ND ND Negative
26 NI 3 Negative ND ND Negative
27 NI 4 Negative ND ND Negative
28 NI 5 Negative ND ND Negative
29 NI 6 Negative ND ND Negative
30 NI 7 Negative ND ND Negative
31 NI 8 Negative ND ND Negative
32 NI 9 Negative ND ND Negative
33 NI 10 Negative ND ND Negative
CI Congenital infection; AI-TXRID Acute infection of Transplanted recipient from infected donor; CCD Chronic Chagas Disease; RCD Reactivated Chagas
Disease; NI Non infected patient.
https://doi.org/10.1371/journal.pntd.0005779.t002
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LAMP was specific for T. cruzi DNA since negative findings were obtained even with high
concentrations (up to 1 pg/μL) of DNAs from T. rangeli (KPN+ and KPN- stocks), P. falcipa-
rum, several Leishmania species, and T. brucei sub-species.
The use of EDTA as anticoagulant proved to be suitable in our study, although it has not
been recommended for LAMP, due to the fact that EDTA competes for manganese ions with
the pyrophosphate ions generated once the reaction starts [27]. Nevertheless, LAMP analysis
carried out using DNA obtained from EDTA-blood samples has also been reported [26]. Since
an easy and quick detection is desirable for application of a LAMP prototype in point-of-care
diagnosis, EDTA-blood samples are appropriate since they are routinely withdrawn in most
health care centers; i.e. for hemogram reports. In fact, we detected up to 1 x 10−2 par. eq./mL
in extracts from spiked EDTA blood samples using fiberglass commercial columns as well as
after Boil & Spin, in accordance to the sensitivity detected by qPCR.
In contrast, when LAMP experiments were performed in heparinized spiked blood using
RAS columns, sensitivity was one order below. Moreover, LAMP results obtained using
30 μL of Boil & Spin DNA preparations from heparinized blood could only be detected after
agarose gel electrophoresis, whereas observation of fluorescence with the naked eye was not
possible: reddish appearance of the contents of tubes hampered visualization (Fig 5B). Direct
visualization was possible only after diluting the DNA extracts at least 1:100 times. However,
the analytical sensitivity in those diluted samples was poor in comparison to the detection
Fig 6. Evaluation of clinical specimens using LAMP assay. A. Visualization by Naked Eye: 1. positive control; 2. CCD6
Chronic Chagas Disease (case 6); 3. NI8: non-infected patient, (case 8); 4. AI-TxRID 2: acute infection of transplanted
recipient from infected donor (case 2); 5. RCD 1: reactivated Chagas disease (case 1); 6. CCD1: chronic Chagas disease 1
(case 1); 7. CI 4: congenital Chagas disease (case 4); 8. negative control. B. Detection of LAMP reaction using Genie III
Fluorimeter. 1: positive control; 2 to 7: clinical specimens indicated in A; 7: Negative control. The Y Axis denotes Fluorescence
and X axis denotes Tt (time when fluorescence passes the threshold).
https://doi.org/10.1371/journal.pntd.0005779.g006
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limit achieved using the other methods; it was only 1 par.eq./mL (S4 Fig). Consequently, the
Boil & Spin procedure used in our study needs to be revised for improvement. It performed
well in other Loopamp kits, such as those developed for Pan/ P. falciparum (27, 28) and
Trypanosoma brucei detection (Standard operating procedures for the Loopamp Trypano-
soma Available: https://www.finddx.org/wp-content/uploads/2016/06/HAT-LAMP-SOP_
13JUN16.pdf).
The analytical sensitivity of this LAMP assay was superior to that previously obtained using
a LAMP procedure based on the 18S rDNA gene [10]. The mentioned study was done using
DNA from Tulahuen strain (Tc VI), and analytical sensitivity was 100 fg per test, using a Real-
time turbidimeter, detection under UV light and direct visualization by the naked eye after 60
minutes of incubation.
To our knowledge, this is the first report of a LAMP kit with similar analytical sensitivity
than Real Time PCR. It was validated using the same T.cruzi strains [16, 28] and using dif-
ferent methods for visualization of amplification. Our data provide evidence of the useful-
ness of this LAMP kit for molecular diagnosis of Chagas disease. Prospective analysis of
clinical specimens will allow establish its performance in different epidemiological and clin-
ical scenarios, such as early diagnosis of congenital infection, POC detection of acute infec-
tions due to oral transmission or in seronegative recipients of organs from seropositive
donors, early detection of reactivation due to immunosuppression due to organ transplanta-
tion or AIDS [3,20,21,22,23,29]. Furthermore, the persistence of positive LAMP results in
patients under etiological treatment could be useful to assess treatment failure [3, 24, 25, 30,
31,32].
Supporting information
S1 Fig. Analytical specificity of qPCR tested in purified DNA from Leishmania major, T.
rangeli and non-infected human DNA. Y axis indicates normalized fluorescence and X axis
denotes Cycles. SPC: Strong positive control: 10 fg/μL of T.cruzi DNA; WPC: weak positive
control: 1 fg/μL of T.cruzi DNA.
(TIF)
S2 Fig. Analytical sensitivity of qPCR for CL Brener stock. qPCR assays were performed
using CL Brener DNA at concentrations ranging from 1 x 10−3 to 1 fg/μL. SPC: Strong positive
control: 10 fg/μL of T.cruzi DNA; WPC: weak positive control: 1 fg/μL of T.cruzi DNA. Y axis
indicates normalized fluorescence and X axis denotes Cycles.
(TIF)
S3 Fig. Analytical sensitivity of qPCR for Sylvio X10 stock. qPCR assays performed using
the same concentrations of Sylvio X10 DNA tested by LAMP. SPC: Strong positive control: 10
fg/μL of T.cruzi DNA; WPC: weak positive control: 1 fg/μL of T.cruzi DNA. Y axis indicates
normalized fluorescence and X axis denotes cycles.
(TIF)
S4 Fig. LAMP assay performed in T. cruzi DNA extracted from spiked heparinized blood
processed by the Boil & Spin method". LAMP test of serial ten-fold dilutions of T.cruzi DNA
extracted from a 104 par.eq./mL spiked heparinized blood sample using Boil & Spin method.
NTC: Negative Control (distilled water); A, 1:10 dilution (10 3 par.eq/mL); B, 1:100 dilution
(10 2 par.eq./mL); C, 1:1000 dilution(10 par.eq./mL); D,1:104 dilution (1 par.eq./mL); 1:105
dilution (E: 10-1 par.eq./mL); NIHB: Non Infected Human Blood; PC: Positive C.
(TIF)
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S5 Fig. Evaluation of clinical specimens using qPCR. NTC: non template control; SPC:
strong positive control; WPC: weak positive control. Clinical samples indicated in Fig 6, panel
A. The Y axis denotes fluorescence and the X axis denotes Cts. control.
(TIF)
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